CureVac N.V.
CVAC
|
$2.51
-3.46%
-3.59%
1.1M
|
Health Technology
(0.0% 1d) (-17.5% 1m) (-64.1% 1y) (0.0% 2d) (2.8% 3d) (6.6% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 561,938,800
http://www.curevac.com
Sec Filling | Patents | 454 employees
(DE) CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
immunotherapy optical t-cell ceiling
add to watch list Paper trade email alert is off
Press-releases
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -5.77%
H: 0.0%
C: 0.0%
start influenza collaboration development study
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -5.77%
H: 0.0%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
business update for financial results
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -5.77%
H: 0.0%
C: 0.0%
business
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
Published: 2024-04-18 (Crawled : 13:00) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -4.32%
H: 0.39%
C: -4.31%
report business update financial results
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -0.38%
H: 3.41%
C: 0.95%
cancer collaboration
Understanding the mRNA Therapeutics Market's -8.6% Decline: Insights from BCC Research
Published: 2024-04-10 (Crawled : 14:30) - prnewswire.com
OMGA | $2.335 -0.21% -0.21% 200K
|
|
| O: -0.33%
H: 0.17%
C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -0.67%
H: 1.36%
C: 0.0%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -1.69%
H: 0.97%
C: 0.14%
mrna research therapeutics
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2024-03-18 (Crawled : 14:00) - prnewswire.com
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.73%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.48%
H: 1.18%
C: 0.08%
ABUS | $2.74 -0.36% -0.36% 340K
|
Health Technology
|
| O: 0.38%
H: 0.38%
C: -3.42%
report genomic market
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung
Published: 2023-11-14 (Crawled : 12:00) - curevac.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.12%
H: 0.14%
C: -0.49%
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: 3.45%
H: 4.56%
C: -0.7%
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10